(Q38702121)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782333%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

CCR5 blockade for neuroinflammatory diseases--beyond control of HIV (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782333%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

0 references

Guillaume Martin-Blondel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782333%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Hans Lassmann

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782333%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Jan Bauer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782333%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Roland Liblau

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782333%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

David Brassat

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782333%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

English

0 references

publication date

18 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782333%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

published in

Nature Reviews Neurology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782333%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782333%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782333%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

95-105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782333%20AND%20SRC:MED&resulttype=core&format=json

Chemokines and chemokine receptors: positioning cells for host defense and immunity

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

The fine balance of chemokines during disease: trafficking, inflammation, and homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

HIV-1 entry inhibitors: recent development and clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Chemokines as regulators of T cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

The role of chemokines in linking innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Chemokines released from astrocytes promote chemokine receptor 5-mediated neuronal cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Expression of the beta-chemokines RANTES and MIP-1 beta by human brain microvessel endothelial cells in primary culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Expression of chemokines and their receptors by human brain endothelium: implications for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Chemokines control naive CD8+ T cell selection of optimal lymph node antigen presenting cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CXCR4-CCR5: a couple modulating T cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Regional and mucosal memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Functional expression of the chemokine receptor CCR5 on virus epitope-specific memory and effector CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Leukocyte migration in the interstitial space of non-lymphoid organs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCR5 expression on monocytes and T cells: modulation by transmigration across the blood-brain barrier in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

The beta chemokines CCL4 and CCL5 enhance adhesion of specific CD4+ T cell subsets to human brain endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Inflammatory chemokine receptors regulate CD8(+) T cell contraction and memory generation following infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Immune subversion by Mycobacterium tuberculosis through CCR5 mediated signaling: involvement of IL-10

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector/memory regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Phenotypic expressions of CCR5-delta32/delta32 homozygosity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Developmental expression patterns of CCR5 and CXCR4 in the rhesus macaque brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Global distribution of the CCR5 gene 32-basepair deletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

The geographic spread of the CCR5 Delta32 HIV-resistance allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

The maraviroc expanded access program - safety and efficacy data from an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Maraviroc for previously treated patients with R5 HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

In vitro effects of the CCR5 inhibitor maraviroc on human T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Effect of maraviroc on HIV disease progression-related biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

HIV-associated neurocognitive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Effect of acute inflammatory brain injury on accumulation of morphine and morphine 3- and 6-glucuronide in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCR2(+)CCR5(+) T cells produce matrix metalloproteinase-9 and osteopontin in the pathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Mimic peptides bonding specifically with the first and second extracellular loops of the CC chemokine receptor 5 derived from a phage display peptide library are potent inhibitors of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

A fusion protein encoding the second extracellular domain of CCR5 arrests chemokine-induced cosignaling and effectively suppresses ongoing experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Astrocytes are a specific immunological target in Rasmussen's encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Hemispherectomy for intractable unihemispheric epilepsy etiology vs outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Pathogenesis of the immune reconstitution inflammatory syndrome affecting the central nervous system in patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8+ T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Immune reconstitution inflammatory syndrome in natalizumab-associated PML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

The chemokine receptor CCR5, a therapeutic target for HIV/AIDS antagonists, is critical for recovery in a mouse model of Japanese encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCR5 deficiency increases risk of symptomatic West Nile virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Polymorphisms in chemokine receptor 5 and Toll-like receptor 3 genes are risk factors for clinical tick-borne encephalitis in the Lithuanian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Association of single nucleotide polymorphism rs3775291 in the coding region of the TLR3 gene with predisposition to tick-borne encephalitis in a Russian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

The role of CC chemokine receptor 5 in antiviral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Chemokine receptor 5 is dispensable for innate and adaptive immune responses to Listeria monocytogenes infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

The cerebral-malaria-associated expression of RANTES, CCR3 and CCR5 in post-mortem tissue samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCR5 deficiency decreases susceptibility to experimental cerebral malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Chemokine and chemokine-receptor expression in human glial elements: induction by the HIV protein, Tat, and chemokine autoregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCR5 knockout prevents neuronal injury and behavioral impairment induced in a transgenic mouse model by a CXCR4-using HIV-1 glycoprotein 120

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: A beneficial antitumor immune response going awry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

The chemokine receptor CCR5 in the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Chemokine receptor CCR5: insights into structure, function, and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Progressive multifocal leukoencephalopathy: why gray and white matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Dynamic imaging of chemokine-dependent CD8+ T cell help for CD8+ T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Trypanosoma cruzi-triggered meningoencephalitis is a CCR1/CCR5-independent inflammatory process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

T cell costimulation by chemokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Maraviroc Intensification of Stable Antiviral Therapy in HIV-1–Infected Patients With Poor Immune Restoration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Identification of cell types producing RANTES, MIP-1 alpha and MIP-1 beta in rat experimental autoimmune encephalomyelitis by in situ hybridization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Macrophage inflammatory protein-1alpha (MIP-1alpha), MIP-1beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.248

Chemokine receptor expression and signaling in macaque and human fetal neurons and astrocytes: implications for the neuropathogenesis of AIDS

31 March 2020

1 reference

12 December 2020

Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates.

1 reference

12 December 2020

Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines.

1 reference

12 December 2020

Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder

1 reference

12 December 2020

Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor

1 reference

12 December 2020

Roles of chemokines and receptor polarization in NK-target cell interactions

1 reference

12 December 2020

Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans

1 reference

12 December 2020

An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection.

1 reference

12 December 2020

10.1038/NRNEUROL.2015.248

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782333%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

5 March 2020

1028210176

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26782333%20AND%20SRC:MED&resulttype=core&format=json